Arbutus Biopharma Corporation

Arbutus Biopharma Corporation a biopharmaceutical company develops novel therapeutics for chronic Hepatitis B virus HBV infection SARSCoV2 and other coronaviruses in the United States Its HBV product pipeline consists of AB729 a proprietary subcutaneously delivered RNA interference product candidate which in Phase IaIb clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated Nacetylgalactosamine GalNAc delivery technology and AB836 an oral capsid inhibitor that suppresses HBV DNA replication The companys research and development programs include AB161 an oral HBV RNA destabilizer to destabilize HBV RNA which leads in the reduction of HBsAg and other viral proteins AB101 an oral PDL1 inhibitor to reawaken patients HBVspecific immune response and small molecule antiviral medicines to treat coronaviruses including COVID19 It has strategic alliance licensing and research collaboration agreements with Talon Therapeutics Inc Gritstone Oncology Inc Alnylam Pharmaceuticals Inc Qilu Pharmaceuticals Co Ltd Assembly Biosciences Inc Acuitas Therapeutics Inc and Antios Therapeutics Inc Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB729 for the treatment of chronic HBV infection The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015 Arbutus Biopharma Corporation is headquartered in Warminster Pennsylvania